NHS England and NHS Improvement\u2019s guidance sets out the support and access for partners and parents of babies in neonatal critical care should be provided by National Health Service trusts. Parents of babies in neonatal critical care are partners in their baby\u2019s care and neonatal units should identify how to safely facilitate parental presence at all times of day.<\/p>
Eligibility for the full or partial payment of NHS travel expenses depends upon being in receipt of a qualifying benefit, being named on an NHS Low Income Scheme and referral by a primary care provider to receive non-primary care services. If these criteria are met individuals would be recompensed for their travel costs. Additionally, trusts have discretion to make a payment if they deem it appropriate.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2021-07-23", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2021-07-23T13:17:48.077Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2021-07-19", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Healthcare Travel Costs Scheme"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 28 June 2021 to Question 20431 on Healthcare Travel Costs Scheme, for what reason providing breastmilk and establishing an attachment with a premature baby is classified as a family visit and not a medical reason for being in hospital under the Healthcare Travel Costs Scheme.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"} } , "tablingMemberConstituency" : {"_value" : "Bristol West"} , "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"} ], "uin" : "35720"} , {"_about" : "http://data.parliament.uk/resources/1347976", "AnsweringBody" : [{"_value" : "Home Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1347976/answer", "answerText" : {"_value" : "
There is more information on referrals available at: Modern Slavery: National Referral Mechanism and Duty to Notify statistics UK, end of year summary 2020 - GOV.UK (www.gov.uk)<\/a><\/p> There is also information available on issues (including modern slavery) raised by people in immigration detention available at: Issues raised by people facing return in immigration detention - GOV.UK (www.gov.uk)<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4399", "label" : {"_value" : "Biography information for Victoria Atkins"}
}
, "answeringMemberConstituency" : {"_value" : "Louth and Horncastle"}
, "answeringMemberPrinted" : {"_value" : "Victoria Atkins"}
, "dateOfAnswer" : {"_value" : "2021-07-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-07-27T15:59:01.58Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "1"}
, "answeringDeptShortName" : {"_value" : "Home Office"}
, "answeringDeptSortName" : {"_value" : "Home Office"}
, "date" : {"_value" : "2021-07-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Slavery: Victim Support Schemes"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for the Home Department, how many criminals and terrorists have been identified as applying for the support available to victims of modern slavery since 2016.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol West"}
, "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"}
], "uin" : "35721"}
, {"_about" : "http://data.parliament.uk/resources/1348066", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1348066/answer", "answerText" : {"_value" : " Trodelvy (sacituzumab govitecan) does not yet have a marketing authorisation for use in Great Britain and is not yet available for routine prescribing. The Medicines and Healthcare products Regulatory Agency is currently considering a marketing authorisation application for Trodelvy through the accelerated process for Project Orbis medicines. The information requested is not held centrally. While the NHS Business Services Authority holds prescription data relating to drugs dispensed within a community setting, no data is collected on the clinical condition of the patient.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2021-07-14", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-07-14T09:42:54.94Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-07-06", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Pancreatic Cancer: Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what proportion of pancreatic cancer patients were prescribed pancreatic enzyme replacement therapy in England in (a) 2015, (b) 2016, (c) 2017, (d) 2018 and (e) 2019.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol West"}
, "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"}
], "uin" : "28227"}
, {"_about" : "http://data.parliament.uk/resources/1344065", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1344065/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) is also currently developing guidance for the National Health Service on whether Trodelvy represents a clinically and cost effective use of NHS resources. It expects to publish draft guidance in spring 2022. Interim access arrangements may be considered for medicines licensed through the Project Orbis pathway where NICE guidance is not anticipated to be published in line with the three month timeframe. NICE and NHS England and NHS Improvement are actively engaging with Gilead to see how interim access arrangements may be applied.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2021-07-27", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2021-07-27T15:06:29.427Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2021-07-19", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Sacituzumab Govitecan"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, when the cancer treatment drug Sacituzumab Govitecan, also known as Trodelvy, will be available for prescription and use in the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4433", "label" : {"_value" : "Biography information for Thangam Debbonaire"}
}
, "tablingMemberConstituency" : {"_value" : "Bristol West"}
, "tablingMemberPrinted" : [{"_value" : "Thangam Debbonaire"}
], "uin" : "35722"}
, {"_about" : "http://data.parliament.uk/resources/1344064", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1344064/answer", "answerText" : {"_value" : "